Jul 26
|
Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment
|
Jul 26
|
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
|
Jul 25
|
Biotech Is Booming, and This Undervalued REIT Stands to Gain
|
Jul 25
|
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
|
Jul 25
|
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
|
Jul 25
|
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
|
Jul 25
|
In reversal, European regulators take positive view on Lilly Alzheimer’s drug
|
Jul 25
|
Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
|
Jul 24
|
Eli Lilly (LLY) Collaborates With Gate Bioscience For Innovative Molecular Gate Therapeutics
|
Jul 24
|
The 3 Things That Matter for Eli Lilly Now
|
Jul 24
|
This Weight-Loss Stock Sank After Earnings. It’s Still a Risk for Eli Lilly, Novo Nordisk.
|
Jul 24
|
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
|
Jul 24
|
Lilly confirms date and conference call for second-quarter 2025 financial results announcement
|
Jul 24
|
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
|
Jul 24
|
Selective Estrogen Receptor Degrader (SERDs) Market Research Report 2025-2030 Featuring AstraZeneca, Eli Lilly, EnhancedBio, Olema Oncology, Radius Therapeutics, and Roche
|
Jul 24
|
West Pharma soars on profit forecast raise, lowered tariff impact estimate
|
Jul 24
|
Lilly and Verve announce expiration of Verve tender offer
|
Jul 24
|
Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
|
Jul 24
|
Benign Breast Disease and Early Breast Cancer Market Analysis Report 2025-2035 | Key Emerging Trends That are Reshaping the Landscape of Diagnosis, Treatment, and Patient Care
|
Jul 23
|
Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results
|